MBX Biosciences, Inc. Common Stock
MBX
About: MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Employees: 43
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]
186% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 14
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
60% more capital invested
Capital invested by funds: $263M [Q1] → $420M (+$157M) [Q2]
10% more funds holding
Funds holding: 79 [Q1] → 87 (+8) [Q2]
3.5% more ownership
Funds ownership: 106.72% [Q1] → 110.22% (+3.5%) [Q2]
48% less call options, than puts
Call options by funds: $848K | Put options by funds: $1.63M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Jefferies
Roger Song
|
$36
|
Buy
Assumed
|
15 Aug 2025 |
|
Mizuho
Uy Ear
|
$38
|
Outperform
Initiated
|
5 Aug 2025 |
|
Oppenheimer
Trevor Allred
|
$38
|
Outperform
Initiated
|
16 Jul 2025 |
Financial journalist opinion
